guidelines focus only on the use of statins, after a detailed review of other cholesterol-lowering drugs. Statins were chosen because their use has resulted in the greatest benefit and the lowest rates of safety issues. No other cholesterollowering drug is as effective as statins, although there is a role for other cholesterol-lowering drugs, for example, in patients who suffer side effects from statins.
The guidelines emphasize that, although other strategies for using drug therapy to reduce atherosclerotic cardiovascular disease (ASCVD) events have been advocated, including treat-to-cholesterol target, lowest is best, and risk-based treatment approaches, only one approach has been de facto evaluated in multiple randomized clinical trials (RCTs)-the use of fixed doses of cholesterol-lowering drugs to reduce ASCVD risk. Because the overwhelming body of evidence comes from statin RCTs, the Expert Panel appropriately focused on these statin RCTs to develop evidence-based guidelines for the reduction of ASCVD risk.
Recommending a practical approach to high LDL-c patients
The new ACC/AHA guidelines [1] recommend moderateor high-intensity statin therapy for these four groups: In addition to identifying patients most likely to benefit from statins, the guidelines outline the recommended intensity of statin therapy for different patient groups. Rather than use a ''lowest is best'' approach that combines a low dose of a statin drug along with several other cholesterol-lowering drugs, the panel found that it can be preferable to focus instead on a healthy lifestyle along with a higher dose of statins, eliminating the need for additional medications. While the focus for years has been on getting the LDL low, these guidelines now say that how you get the LDL low is important.
Why staying out of the target concept?
The concept of treating to a target level of LDL cholesterol comes from the commonly used and sensible practice of calibrating the intensity of any preventive treatment to the level of the baseline risk, with the awareness that any pharmacological treatment has downsides, and therefore, going down across the risk spectrum, one should-sooner or later-find an ''equipoise'', a level of risk below which the expected benefits of a treatment are outweighed by its inherent risk. This risk assessment-based approach is used commonly in most areas of Medicine, for example in deciding whether or not to prescribe aspirin in people without evidence of previous cardiovascular disease [4] . Setting more and more stringent criteria when the risk of future cardiovascular events gets higher also helps remind doctors that their alertness should be maximum in subjects at highest risk, and an intensified therapy has to be pursued in higher risk categories.According to these principles, the 2011 ESC guidelines [3] , in a specific paragraph named ''Treatment targets'', recommended a tailoring of treatment according to the baseline risk, defined according to the SCORE calculations [5] , assessing the 10-year risk of fatal cardiovascular disease. According to this, in patients at very high CV risk (a SCORE level [10 %), a target of \70 mg/dL (1.8 mmol/L) is recommended; but more lenient targets are recommended for patients at high CV risk (SCORE level [5 %)-in this case \100 mg/dL or 2.5 mmol/L)-, and even more lenient targets for patients at moderate risk (SCORE level 1.5)-in this case 115 mg/ dL, or 3.0 mmol/L.
The explicit justification for this approach is, however, vague: ''The overall guidelines on CVD prevention in clinical practice strongly recommend modulating the intensity of the preventive intervention according to the level of the total CV risk. Therefore, the targets should be less demanding when the total CV risk decreases from very high to high or moderate'' [3] . Indeed those very same ESC guidelines cite that the most recent Cholesterol Treatment Trialists' Collaboration (CTT) meta-analysis of several trials involving [170,000 patients, which confirmed the dose-dependent reduction in CVD with LDL-C lowering [6] . The Interpretation paragraph in the abstract of that publication explicitly states: ''Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1.0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth. There was no evidence of any threshold within the cholesterol range studied, suggesting that reduction of LDL cholesterol by 2-3 mmol/L would reduce risk by about 40-50 %'' [6] .
Although side effects of statins-by far the best studied approach to reduce LDL cholesterol-are known to be dose-dependent [7] , analysis of risk associated with statin treatment also in low-risk populations (with 5-year risk of major vascular events lower than 10 %) has shown a persistence of benefits outweighing the risk [8] . Although benefit may not include a reduction in mortality in primary prevention [9] , there still appears to be an effect on important non-fatal events such as non-fatal myocardial infarction, stroke, or coronary revascularization [8] . In addition to being associated with a favorable efficacysafety balance, with the emergence of generic high-potency statins, such as atorvastatin and-soon-rosuvastatin, statin therapy is also increasingly becoming cost-effective, and most of thecounterpoints for a wide adoption of their use appear to be minimized [10] .
It is true that safety, as reported from clinical trials, is underestimated because of the upstream exclusion from trials of patients experiencing side effects [11] . But statin safety can in most cases easily be assessed in a run-in period [7] , so that the justification for withholding a highpotency weapon, such as atorvastatin 40-80 mg/day or rosuvastatin 20-40 mg/day, in healthy persons at risk because they have already reached their lenient target of 115 mg/dL (3 mmol/L) of LDL cholesterol [3] , appears not to be scientifically sound. Incidentally, the reduction of such target value from the previous one of 130 mg/dL [2] appears more a kind of compromise to accommodate new facts into an old scheme, than an act of courage to abandon old paradigms. Given the absence of data on titration of drug therapy to specific goals, no recommendations are, therefore, made in the latest ACC/AHA Guidelines [1] for or against specific LDL cholesterol or non-HDL cholesterol goals for the primary or secondary prevention of ASCVD.
The impact of this change in paradigm
The likely impact of the new ACC/AHA recommendations is that-if doctors will adhere to these recommendations-more people who would benefit from statins are going to be on them. Doctors may also consider switching some patients to a higher dose of statins to derive greater benefit as a result of this approach focusing on the immediate use of a moderate-or high-intensity statin treatment in most individuals at risk. I support this position.
